GSK-923295: Selective CENP-E Inhibition for Targeted Mitotic Arrest

Executive Summary: GSK-923295 is a potent, selective small-molecule inhibitor of centromere-associated protein E (CENP-E) with a Ki of 3.2 nM, validated to arrest cells at mitosis by stabilizing the ATP-bound form of CENP-E and suppressing its microtubule-stimulated ATPase activity (APExBIO product page). In vitro, GSK-923295 inhibits tumor cell proliferation across 237 lines with a median GI50 of 32 nM. In vivo, 125 mg/kg intraperitoneal administration in Colo205 colon tumor xenografts results in dose-dependent tumor regression and increased apoptosis. The mechanism recapitulates CENP-E depletion phenotypes including chromosome misalignment, supporting its use for dissecting mitotic checkpoint signaling and chromosome congression (see detailed review). Storage and solubility parameters are defined for reproducible experimental setup. GSK-923295 is supplied by APExBIO for research use only, not for human diagnostics or therapy.

Biological Rationale

Mitosis ensures accurate chromosome segregation through the orchestration of spindle microtubules, kinetochores, and centromere-associated proteins. CENP-E, a kinesin motor, links spindle microtubules to kinetochores, integrating checkpoint signaling with chromosome alignment and promoting the metaphase-anaphase transition (see GSK-923295: A Next-Generation Tool). Disruption of this process results in missegregation, aneuploidy, and is implicated in cancer pathogenesis (CTCF Ensures Centromere Integrity). Recent studies distinguish CENP-E’s role in chromosome congression from other centromere maintenance factors such as CTCF, which supports centromere structure but does not mediate CENP-E recruitment (CTCF Safeguards Centromere Architecture). Thus, a selective CENP-E inhibitor like GSK-923295 is uniquely positioned to dissect the mechanistic basis of mitotic fidelity and chromosome alignment regulation in cancer research.

Mechanism of Action of GSK-923295

GSK-923295 exerts its effects by binding to CENP-E and inhibiting its microtubule-stimulated ATPase activity, stabilizing the ATP-bound conformation and slowing the release of ADP and inorganic phosphate (product information). This inhibition prevents proper chromosome congression and silences mitotic checkpoint signaling, leading to robust metaphase arrest. The resulting phenotype closely mirrors RNAi-mediated CENP-E depletion, including persistent unaligned chromosomes at the spindle equator and activation of spindle assembly checkpoint proteins (GSK-923295 and the New Frontier). The molecular weight of GSK-923295 is 592.14; it is a solid, soluble at ≥29.6 mg/mL in DMSO or ≥14.87 mg/mL in ethanol (with sonication), but insoluble in water. Recommended storage is at -20°C with prompt use of solutions to minimize degradation (APExBIO).

Evidence & Benchmarks

• GSK-923295 binds CENP-E with a Ki of 3.2 nM, indicating high affinity and specificity (APExBIO product information).
• In vitro, GSK-923295 inhibits tumor cell growth across 237 human tumor cell lines with an average GI50 of 253 nM and a median GI50 of 32 nM (detailed review).
• In vivo, 125 mg/kg intraperitoneal administration in Colo205 colon tumor xenograft mice yields dose-dependent tumor regression and increased apoptosis (protocols and benchmarks).
• Phenotypic response to GSK-923295 recapitulates CENP-E knockdown, with accumulation of cells in mitotic arrest and failure of chromosome alignment (mechanistic overview).
• CTCF depletion does not prevent CENP-E recruitment but disrupts centromere structure and metaphase plate organization, highlighting distinct mechanistic roles (CTCF Safeguards Centromere Architecture).

Applications, Limits & Misconceptions

GSK-923295 is widely used in cancer research to induce cell cycle arrest in mitosis and probe the role of chromosome alignment mechanisms. It is particularly effective in models where CENP-E function is required for tumor cell proliferation, such as colon cancer xenografts. However, the efficacy and specificity of GSK-923295 are context-dependent, and it is not intended for diagnostic or therapeutic human use (APExBIO terms).

Common Pitfalls or Misconceptions

• GSK-923295 does not inhibit centromere structure maintenance proteins such as CTCF or cohesin; its effects are restricted to CENP-E-mediated processes.
• It is not water-soluble; improper solvent use may lead to precipitation and loss of activity.
• Over-dilution or delayed use of prepared solutions can result in degradation and reduced efficacy.
• GSK-923295 is not a pan-mitotic inhibitor; it does not disrupt all mitotic kinases or microtubule motors.
• Experimental results may not translate directly to clinical efficacy due to tumor heterogeneity and pharmacokinetic variables.

Workflow Integration & Parameters

• Dissolution: Dissolve GSK-923295 at ≥29.6 mg/mL in DMSO or ≥14.87 mg/mL in ethanol with sonication; prepare fresh aliquots for each experiment (APExBIO).
• Storage: Store solid GSK-923295 at -20°C; avoid repeated freeze-thaw cycles.
• In vitro cell assays: Typical working concentrations range from 10–500 nM; titrate as needed for specific cell lines (benchmark reference).
• In vivo studies: Intraperitoneal administration in mice at 125 mg/kg for tumor xenografts shows dose-dependent efficacy; monitor for apoptosis and regression endpoints (protocols).
• Phenotypic controls: Use RNAi or CRISPR knockdown of CENP-E for comparison to validate specificity of GSK-923295-induced arrest (mechanistic controls).

Conclusion & Outlook

GSK-923295, sourced from APExBIO, is a rigorously benchmarked CENP-E inhibitor enabling precise dissection of mitotic checkpoint and chromosome alignment mechanisms. Its selectivity for CENP-E and robust in vitro and in vivo activity make it indispensable for cancer research focusing on mitotic regulation. Distinguishing its effects from those of centromere architecture proteins such as CTCF allows for refined experimental design and interpretation. Ongoing studies leverage GSK-923295 to bridge basic centromere biology with translational oncology, but its application remains limited to preclinical research settings (see centromere study).